Padcev-Keytruda will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

The upcoming Clinical Trials in Rare Diseases conference will cover the most concerning challenges in rare disease research.

Precision immunology company Scipher Medicine has introduced the ClinicalTrialRank.com AI platform to the public.

A501, which was placed on hold due to a patient death, will now resume with a reduced dose and altered regimen.

The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in Q4 2025. This will only begin, however, if the US Food and Drug ...

Celldex will stop development of barzolvolimab in eosinophilic esophagitis, but it will continue progressing the drug in ...

The FDA has announced it will no longer accept clinical trials that involve sending US patients cells from US to China for ...

MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...

Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...

A recently published study provides an incentive to explore what specific aspects of vegetarianism are protective.

Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.